ArticleFrontiers in cell and developmental biology2021
NUCB1 Suppresses Growth and Shows Additive Effects With Gemcitabine in Pancreatic Ductal Adenocarcinoma via the Unfolded Protein Response.
Article in Frontiers in cell and developmental biology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it, 37 citations in OpenAlex.
- Pooled it
- The METTL3 inhibitor STM2457 suppresses gastric cancer progression by modulating m6A RNA modification.PloS one · 2026Article
- Multi-Omics Alterations in Rat Kidneys upon Chronic Glyphosate Exposure.Biomolecules · 2025Article
- Revealing tumor microenvironment communication through m6A single-cell analysis and elucidating immunotherapeutic potentials for cutaneous melanoma (CM).Journal of cancer research and clinical oncology · 2025Article
- Cell-death induced immune response and coagulopathy promote cachexia inbioRxiv : the preprint server for biology · 2025Article
- The Mechanism and Latest Progress of m6A Methylation in the Progression of Pancreatic Cancer.International journal of biological sciences · 2025Review
- Autophagy: a critical mechanism of NCell death & disease · 2024Review
- WTAP/IGF2BP3-mediated GBE1 expression accelerates the proliferation and enhances stemness in pancreatic cancer cells via upregulating c-Myc.Cellular & molecular biology letters · 2024Article
- Platelet proteo-transcriptomic profiling validates mediators of thrombosis and proteostasis in patients with myeloproliferative neoplasms.bioRxiv : the preprint server for biology · 2023Article
- Aberrant RNA mCell death & disease · 2023Review
- METTL3 enhances pancreatic ductal adenocarcinoma progression and gemcitabine resistance through modifying DDX23 mRNA N6 adenosine methylation.Cell death & disease · 2023Article
- Roles of RNA Methylations in Cancer Progression, Autophagy, and Anticancer Drug Resistance.International journal of molecular sciences · 2023Review
- Review
- Development and validation of a tumor immune cell infiltration-related gene signature for recurrence prediction by weighted gene co-expression network analysis in prostate cancer.Frontiers in genetics · 2023Article
- Role of NInternational journal of oncology · 2023Review
- Epigenetic reprogramming in pancreatic premalignancy and clinical implications.Frontiers in oncology · 2023Review
- N6-methyladenosine reader YTHDF family in biological processes: Structures, roles, and mechanisms.Frontiers in immunology · 2023Review
- Recent Advances in RNA mCancer treatment and research · 2023Article
- Label-Free Quantitative Proteomics Analysis of Adriamycin Selected Multidrug Resistant Human Lung Cancer Cells.Biomolecules · 2022Article
- Research advances of N6-methyladenosine in diagnosis and therapy of pancreatic cancer.Journal of clinical laboratory analysis · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive cancer with poor patient prognosis. A cellular stress response mechanism called the unfolded protein response (UPR) has been implicated in PDAC progression. More recently, nucleobindin 1 (NUCB1), a calcium-binding protein, has been shown to control the UPR but its precise role in PDAC has not been explored. Here, we found that downregulation of NUCB1 was associated with poor prognosis in patients with PDAC. Functionally, NUCB1 overexpression suppressed pancreatic cancer cell proliferation and showed additive effects with gemcitabine (GEM)
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.